LITHIUM CITRATE
LOE ApproachingNDAORALSYRUP
Approved
Dec 1980
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
3/8 — Basic
LITHIUM CITRATE by Hikma is 12 clinical. First approved in 1980.
Drug data last refreshed 43m ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Lithium citrate is an oral syrup small-molecule mood stabilizer indicated for bipolar disorder, though its exact mechanism of action remains unknown. It is completely absorbed from the upper GI tract, distributes across total body water, and is excreted unchanged via the kidneys with an 18–36 hour half-life. The product has been approved since 1980 and remains a foundational psychiatric therapeutic.
$0.004BPart D
LOE ApproachingMature product with minimal Part D spend ($4K, 25 claims in 2023) signals a stable but contracted franchise approaching loss of exclusivity; smaller marketing and field teams are typical.
Mechanism of Action
12 CLINICAL. PHARMACOLOGY 12.1 Mechanism of Action The mechanism of action of lithium as a mood stabilizing agent is unknown. 12.3 Pharmacokinetics Absorption: After oral administration, lithium is reported to be completely absorbed in the upper gastrointestinal tract. Peak serum concentrations (T…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Worked on LITHIUM CITRATE at Hikma? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.